824
Views
26
CrossRef citations to date
0
Altmetric
Original Article: Research

Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

, , , , &
Pages 786-797 | Received 29 Oct 2007, Accepted 19 Jan 2008, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (8)

Mohammad Hassan Hodroj, Achraf Jardaly, Sarah Abi Raad, Annalise Zouein & Sandra Rizk. (2018) Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway. Cancer Management and Research 10, pages 1079-1088.
Read now
Zhanyong Li, Nataliia I. Shtemenko, Dina Y. Yegorova, Svetlana O. Babiy, Andrew J. Brown, Tinglu Yang, Alexander V. Shtemenko & Kim R. Dunbar. (2015) Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity. Journal of Liposome Research 25:1, pages 78-87.
Read now
Niamh Keane, Ciara Freeman, Ronan Swords & Francis J Giles. (2013) Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. Expert Review of Hematology 6:1, pages 9-24.
Read now
Katarzyna Jamieson & Olatoyosi Odenike. (2012) Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia. Expert Opinion on Pharmacotherapy 13:15, pages 2171-2187.
Read now
Aine Carol Burke & Frank James Giles. (2011) Elacytarabine – lipid vector technology overcoming drug resistance in acute myeloid leukemia. Expert Opinion on Investigational Drugs 20:12, pages 1707-1715.
Read now
Awa Dicko, Lawrence D Mayer & Paul G Tardi. (2010) Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo . Expert Opinion on Drug Delivery 7:12, pages 1329-1341.
Read now
Bhupender S Chhikara & Keykavous Parang. (2010) Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opinion on Drug Delivery 7:12, pages 1399-1414.
Read now
Yesid Alvarado, Ronan Swords, Kevin R Kelly & Francis J Giles. (2009) Clinical activity of laromustine (Onrigin™) in hematologic malignancies. Expert Review of Hematology 2:5, pages 481-488.
Read now

Articles from other publishers (18)

Benjamin Heyman, David Rizzieri, David J. Adams, Carlos De Castro, Louis Diehl, Zhiguo Li, Joseph Moore & Anne Beaven. (2018) Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:10, pages 679-686.
Crossref
Nikolaos Tsesmetzis, Cynthia Paulin, Sean Rudd & Nikolas Herold. (2018) Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers 10:7, pages 240.
Crossref
Bingjun Sun, Cong Luo, Weiping Cui, Jin Sun & Zhonggui He. (2017) Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy. Journal of Controlled Release 264, pages 145-159.
Crossref
Peter Alexander, Gregory Kucera & Timothy S. Pardee. (2016) Improving nucleoside analogs via lipid conjugation: Is fatter any better?. Critical Reviews in Oncology/Hematology 100, pages 46-56.
Crossref
Lindsay A. M. Rein & David A. Rizzieri. (2014) Clinical potential of elacytarabine in patients with acute myeloid leukemia. Therapeutic Advances in Hematology 5:6, pages 211-220.
Crossref
Rana Khalife, El-Hayek Stephany, Omayr Tarras, Mohammad Hassan Hodroj & Sandra Rizk. (2014) Antiproliferative and Proapoptotic Effects of Topotecan in Combination With Thymoquinone on Acute Myelogenous Leukemia. Clinical Lymphoma Myeloma and Leukemia 14, pages S46-S55.
Crossref
Kendra Sweet & Jeffrey E. Lancet. (2014) Novel Therapeutics in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports 9:2, pages 109-117.
Crossref
Courtney D DiNardo, Susan O’Brien, Varsha V Gandhi & Farhad Ravandi. (2013) Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncology 9:8, pages 1073-1082.
Crossref
Susan O'Brien, David A. Rizzieri, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, Mike Dennis, Adriano Venditti, Donald A. Berry, Tove Flem Jacobsen, Karin Staudacher, Trygve Bergeland & Francis J. Giles. (2012) Elacytarabine has single‐agent activity in patients 
with advanced acute myeloid leukaemia. British Journal of Haematology 158:5, pages 581-588.
Crossref
F J Giles, N Vey, D Rizzieri, F Ravandi, T Prebet, G Borthakur, T F Jacobsen, S Hagen, B Nilsson & S O'Brien. (2012) Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia 26:7, pages 1686-1689.
Crossref
Barry D. Liboiron, Paul G. Tardi, Troy O. Harasym & Lawrence D. Mayer. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology 1013 1050 .
David J. Adams, William R. Waud, Mansukh C. Wani, Govindarajan Manikumar, James L. Flowers, Timothy A. Driscoll & Lee Roy Morgan. (2010) BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. Cancer Chemotherapy and Pharmacology 67:4, pages 855-865.
Crossref
Wah-Seng Lim, Paul G. Tardi, Nancy Dos Santos, Xiaowei Xie, Mannie Fan, Barry D. Liboiron, Xiaoping Huang, Troy O. Harasym, David Bermudes & Lawrence D. Mayer. (2010) Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leukemia Research 34:9, pages 1214-1223.
Crossref
Gary J. SchillerSusan M. O'BrienArnaud PigneuxDaniel J. DeAngeloNorbert VeyJonathan KellScott SolomonRobert K. StuartVerena KarstenAnn L. CahillMaher X. AlbitarFrancis J. Giles. (2010) Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia. Journal of Clinical Oncology 28:5, pages 815-821.
Crossref
Troy O. Harasym, Barry D. Liboiron & Lawrence D. Mayer. 2010. Multi-Drug Resistance in Cancer. Multi-Drug Resistance in Cancer 291 323 .
Paul G. Tardi, Nancy Dos Santos, Troy O. Harasym, Sharon A. Johnstone, Natalia Zisman, Alan W. Tsang, David G. Bermudes & Lawrence D. Mayer. (2009) Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo . Molecular Cancer Therapeutics 8:8, pages 2266-2275.
Crossref
Karen L. Morris, Julie A. Adams & John A. Liu Yin. (2009) Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin. Leukemia Research 33:8, pages 1096-1099.
Crossref
Carlos M. Galmarini, Finn Myhren & Marit L. Sandvold. (2009) CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. British Journal of Haematology 144:2, pages 273-275.
Crossref